By: IPP Bureau
Last updated : July 02, 2026 8:55 pm
During his thirteen years at Biocon, Siddharth held the position of Chief Financial Officer, leading many strategic partnerships and commercial initiatives
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has appointed Siddharth Mittal as the Managing Director and Chief Executive Officer of the Company, effective 1 July 2026.
Mittal succeeds Peter Bains, who completed his tenure as Managing Director & CEO on 30 June 2026, bringing close to three decades of business leadership experience.
He joins Syngene from Biocon Limited, where he most recently served as the Managing Director and Chief Executive Officer.
During his thirteen years at Biocon, Siddharth held the position of Chief Financial Officer, before being appointed Managing Director and CEO.
During this period, he played a pivotal role in shaping the strategic direction of the company that positioned it for long term growth, strengthening its commercial operations, expanding its presence across global markets, securing key regulatory approvals and successfully commercializing Biocon's GLP-1 portfolio across major international markets.
He also led strategic partnerships and commercial initiatives that strengthened Biocon's competitive position while driving operational excellence, customer-centricity and sustainable business growth.
Kiran Mazumdar-Shaw, Executive Chairperson, Syngene International, said: "I am delighted to welcome Siddharth as the Managing Director and CEO of Syngene. Having worked closely with Siddharth for many years, I have seen first hand his ability to lead businesses through period of change, build strong teams and deliver transformation and sustainable growth.”
Commenting on taking on the role, Siddharth Mittal said: "I am honoured to take on the role of Managing Director and CEO of Syngene. Over the years, the company has built exceptional scientific capabilities, a talented team, and gained the trust of customers across the world. These enduring strengths give us a solid platform to drive the next phase of long-term growth.”
“My immediate priority is to sharpen our commercial edge, strengthen delivery excellence and bring greater focus and discipline to execution across the business. I am confident that we can restore growth momentum and reinforce Syngene’s standing as a global leader in CRDMO services, while creating long-term value for all our stakeholders,” he added.